Factors Associated With Biologic DMARD Switching

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4099 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Primary objective of this study is to understand the rheumatoid arthritis (RA) population in national integrated delivery network who are treated with first- or second-line biologic disease modifying anti-rheumatic drug (bDMARD) therapy (with or without Methotrexate) and to evaluate switching patterns and reasons for switching to another bDMARD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)

NCT01136694

Rheumatoid Arthritis

COMPLETED

Impact Of RA Therapy Compliance On Patient-Reported Outcomes

NCT01438892

Rheumatoid Arthritis

COMPLETED

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382

Rheumatoid Arthritis

COMPLETED PHASE3

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

NCT02557100

Rheumatoid Arthritis

COMPLETED PHASE4

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

NCT00069017

Rheumatoid Arthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who have no history of bDMARD therapy use

No interventions assigned to this group

Patients who have a prior history of bDMARD therapy use

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of RA (ICD-9 714.xx) anytime during the study time period of 1/1/2007 to 10/31/2012
* Patients ≥18 years of age at diagnosis date
* Required to have to have 6 months pre-index and 12 months post-index continuous membership and drug benefit eligibility in the database

Exclusion Criteria

* Patients less than 18 years of age on diagnosis date
* If they had a diagnosis of Crohn's disease, psoriasis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, regional enteritis, or anal fistula during the pre-index period
* Patients who had \<7 days supply of adalimumab or etanercept
* Patients currently in a clinical trial during our study
* If patients are in the second-line cohort and have more than 1 prior bDMARD

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No